# US 2018/0022715 A1 · N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022715 A1
- Document ID: US20180022715A1
- Status: Published application
- Kind: A1
- Application number: 15/547,779
- Filed: 2016-02-15
- Published: 2018-01-25
- Earliest claimed: 2015-02-16
- Assignees: Glucox Biotech AB
- Applicants: Glucox Biotech AB
- Inventors: Per Wikström; Erik Walum; Mona Wilcke
- Web page: https://patentgrep.com/patent/US20180022715A1

## CPC

- C07D 251/18: with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The compound N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamineor a pharmaceutically acceptable salt of said compound. The compound is useful the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidaseactivity. A pharmaceutical composition comprising the compound.

## Claims

### Claim 1

The compound
N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine, or a pharmaceutically acceptable salt of said compound.

### Claim at position 2

-4. (canceled)

### Claim 5 (depends on 1)

A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt according to claim 1 and optionally a pharmaceutically acceptable excipient.

### Claim at position 4

-16. (canceled)

### Claim 17

A method of treatment of a condition or disorder selected from endocrine disorders, cardiovascular disorders, respiratory disorders, metabolism disorders, skin disorders, bone disorders, neuroinflammatory and/or neurodegenerative disorders, kidney diseases, reproduction disorders, diseases affecting the eye and/or the lens and/or conditions affecting the inner ear, inflammatory disorders, liver diseases, pain, cancers, allergic disorders, traumatisms, septic, hemorrhagic and anaphylactic shock, diseases or disorders of the gastrointestinal system, abnormal angiogenesis and angiogenesis-dependent conditions, lung infections, acute lung injury, pulmonary arterial hypertension, obstructive lung disorders, and fibrotic lung disease, by administering the compound N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine, or a pharmaceutically acceptable salt of said compound, to a mammal in need of such treatment.

### Claim 18 (depends on 17)

The method of claim 17, wherein the mammal is a human.

### Claim 19 (depends on 17)

The method of claim 17, wherein the mammal is a non-human mammal.

### Claim 20 (depends on 17)

The method of claim 17, wherein the non-human mammal is a dog or a cat.

### Claim 21 (depends on 17)

The method of claim 17, wherein the disorder or condition is selected from diabetes, stroke, fibrosis, neuropatic pain and diabetes complication.

### Claim 22 (depends on 17)

The method of claim 17, wherein the disorder or condition is diabetes.

### Claim 23 (depends on 17)

The method of claim 17, wherein the fibrosis is lung fibrosis.

### Claim 24 (depends on 17)

The method of claim 17, wherein the diabetes complication is neuoropathy.

### Claim 25 (depends on 1)

A veterinary composition comprising the compound or the pharmaceutically acceptable salt according to claim 1 and optionally an excipient acceptable for veterinary use.
